… of oral anticoagulation therapy for real-world atrial fibrillation patients with an elevated risk
of stroke, highlighting the need for improved therapies for stroke prevention in atrial fibrillation. …

… the novel oral anticoagulants with the vitamin K antagonists in patients with atrial fibrillation.
We … We found that the novel oral anticoagulants significantly reduced overall mortality, …

… France; anticoagulation clinics in Italy and Spain) and data pertaining to their oral anticoagulation
care … The predominant anticoagulant in use was warfarin in the US, Canada, and Italy; …

… Atrial fibrillation (AF) is a major risk factor for stroke. Currently, acetylsalicylic acid (a platelet
inhibitor) and vitamin K antagonists (VKAs; oral anticoagulants), including warfarin, are the …

… of stroke in patients with atrial fibrillation is greatly reduced by oral anticoagulation, with
the full … The effect of the intensity of oral anticoagulation on the severity of atrial fibrillation–related …

… Oral anticoagulation (OAC) is recommended to reduce the risk of stroke associated with
nonvalvular atrial fibrillation … Warfarin is the most widely prescribed oral anticoagulant in the …

… Atrial fibrillation (AF) is a major risk factor for thromboembolism, and oral anticoagulation
therapy (OAT) is usually recommended for patients at higher risk of this complication (1,2). …

… atrial fibrillation, … oral anticoagulant OR NOAC OR direct oral anticoagulant OR DOAC OR
apixaban OR dabigatran OR rivaroxaban OR edoxaban OR anticoagulation OR anticoagulant. …

… Stroke prevention with oral anticoagulants (OACs) is the cornerstone for the management
of atrial fibrillation (AF). However, data about the use of OACs among patients ≥90 years of …

… of oral anticoagulants vs aspirin (with or without low-dose warfarin) is presented for all 6
outcomes as a hazard ratio. Hazard ratios below 1 indicate that oral anticoagulant decreases …